SNHG14 (Small Nucleolar RNA Host Gene 14)

HPSE2 has the most interaction nodes among mRNAs, hsa-miR-17-5p among miRNAs, and Lnc SNHG14 among lncRNAs in the ceRNA network. The findings suggest that the m1A regulator TRMT6 may drive ovarian cancer progression by promoting immune escape.

Overall, SNHGs may serve as molecular biomarkers and hold potential therapeutic target value. However, existing evidence is largely based on in vitro and small-sample studies, requiring further validation in clinical cohorts and functional models.

Perindopril inhibits myocardial apoptosis in mice with acute myocardial infarction through TLR4/NF-κB pathway...SNHG7 mediates cisplatin-resistance in non-small cell lung cancer by activating PI3K/AKT pathway...Natural killer cell-derived exosome-entrapped paclitaxel can enhance its anti-tumor effect...Antidiabetic drug metformin mitigates ovarian cancer SKOV3 cell growth by triggering G2/M cell cycle arrest and inhibition of m-TOR/PI3K/Akt signaling pathway...These articles have been retracted. The Publisher apologizes for any inconvenience this may cause.

Selected lncRNAs, including THOR and LINC01094, have also demonstrated significant prognostic value. Despite these advances, challenges persist, including inconsistent reporting, limited external validation, and a lack of replication by independent research groups.

Given the nature of the concern, the editors consider the results and conclusions of this article invalid. The authors did not respond to our notice of retraction.

Given the nature of the concern, the editors consider the results and conclusions of this article invalid. The authors were informed of the retraction.

Plasminogen activator urokinase receptor was differently expressed and positively correlated with an unfavorable prognosis in NSCLC. The MIRLET7BHG/hsa-miR-127-3p axis was identified as the most likely upstream ncRNA-related pathway for PLAUR in NSCLC. This study provides insights into the molecular mechanism of action of PLAUR in NSCLC, which may help to develop new drugs to regulate PLAUR expression or its function in tumor development and provide new targets for the treatment of NSCLC.

Significant differences (P<0.05) were found between the high and low risk groups in terms of immune function and half-maximal inhibitory concentration (IC50) values of five anticancer drugs (doxorubicin, lapatinib, paclitaxel, savolitinib and trametinib). We also identified a lncRNA SNHG14 /hsa-miR-101-3p/KL/PLK1 regulatory axis for LUAD. The survival prognosis model of NRGs constructed in this study can predict the prognosis and immune microenvironment of LUAD patients.

Therefore, our research findings suggested a novel pathway to promote GC progression through the FNDC3A/lncRNA SNHG14/miR-206/FNDC3A axis. Moreover, the findings indicated that SNHG14 could become a potential biomarker and therapeutic target for GC.

The Publisher apologizes for any inconvenience this may cause. https://www.europeanreview.org/article/17790.

The Publisher apologizes for any inconvenience this may cause. https://www.europeanreview.org/article/23391.

Our findings suggest that SNHG14 expression could serve as a potential biomarker for prognosing adult non-M3 AML patients. Furthermore, SNHG14 may offer insights into novel therapeutic targets for this subset of AML patients.